AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Soligenix stock surges 50% after positive Phase 2a study results for Behçet’s Disease treatment
ByAinvest
Saturday, Aug 2, 2025 4:08 pm ET1min read
Soligenix (SNGX) stock surged 52.8% on Thursday after announcing positive results from its Phase 2a proof-of-concept study for SGX945, a treatment for Behçet's Disease. The company found a 40% improvement rate after four weeks compared to a Phase 3 apremilast study. Heavy trading volume of 52 million shares was seen, with one analyst recommending a buy rating and a 380% upside potential.
Soligenix Inc. (SNGX) stock surged by 52.8% on Thursday following the announcement of positive results from its Phase 2a proof-of-concept study for SGX945, a potential treatment for Behçet's Disease. The study, which evaluated dusquetide (SGX945) in patients with mild to moderate Behçet's Disease, demonstrated a 40% improvement in oral ulcers compared to placebo after four weeks of treatment. This improvement was sustained even after treatment cessation, indicating a durable biological effect.The study, an open-label trial, was designed to be highly comparable to the previously published Phase 3 study of apremilast (Otezla), an approved treatment for oral ulcers associated with Behçet's Disease. Dusquetide showed similar results to apremilast in reducing oral ulcers, pain, and ulcer duration. Notably, dusquetide treatment did not result in any adverse effects, such as nausea or diarrhea, which are common with apremilast.
Soligenix plans to reformulate SGX945 for home-based treatment using subcutaneous injection and expand its use in other inflammatory conditions. The company aims to conduct a placebo-controlled Phase 2 study to further validate the promising initial results and establish the efficacy profile of SGX945 in Behçet's Disease.
The stock's performance was driven by heavy trading volume, with 52 million shares changing hands. One analyst recommended a buy rating, predicting a 380% upside potential.
References:
[1] https://www.dermatologytimes.com/view/soligenix-reports-positive-phase-2a-data-in-beh-et-s-disease
[2] https://www.stocktitan.net/news/SNGX/biological-efficacy-demonstrated-in-a-phase-2-clinical-trial-of-ybrmt1wzku7h.html
[3] https://www.marketscreener.com/news/soligenix-inc-biological-efficacy-demonstrated-in-a-phase-2-clinical-trial-of-sgx945-for-the-tre-ce7c5fd3d988f022
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet